Mutual of America Capital Management 13F: Adds $2.6M to CORT Stake

Mutual of America Capital Management raised its holdings in Corcept Therapeutics Incorporated CORT by 191.4%, boosting its stake by 22,794 shares during the period according to a Form 13F filing with the SEC on October 23, 2026. The firm ended the quarter with 34,702 shares valued at about $3,998,712.

CORT Corcept Therapeutics Incorporated

$85.86 ▲ +124.76% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mutual of America's Corcept Therapeutics Position

The institutional investor lifted its investment significantly, taking its prior count of 11,908 shares up to a new total of 34,702 shares. That addition represents a 191.4% increase for the fund's holdings in the biopharmaceutical developer.

Other Institutional Activity in Corcept Therapeutics

Ingalls & Snyder LLC grew its holdings by 325,659 shares, ending with 7,934,507 shares worth about $681,256,775. Renaissance Technologies, LLC reduced its stake by 421,089 shares, closing the period with 5,261,628 shares valued at approximately $451,763,383. Parallel Advisors, LLC trimmed 15,114 shares for a 0.4% decrease, finishing with 3,962,177 shares worth roughly $340,192,519. AQR Capital Management, LLC expanded its position dramatically by 2,176,357 shares, which works out to a 535.8% jump that left it holding 2,582,561 shares valued at about $221,738,689.

Corcept Therapeutics Incorporated Stock Down 26.2%

Shares of Corcept Therapeutics closed at $85.86 on October 23, 2026, and recently traded around $85.86 as of October 24, 2026. The stock sits below its 52-week high of $126.38 and well above its 52-week low of $28.66.

Recent Earnings

The company generated $830,812,992 in trailing twelve-month revenue with an EPS of $0.45. Its net profit margin stands at 6.6% with a return on equity of 8.2%.

Insider Buying and Selling at Corcept Therapeutics Incorporated

Chief Technology Officer Joseph Douglas Lyon disposed of 10,000 shares on October 2, 2026, valued at $1,160,731. Officer Roberto W Vieira sold 8,333 shares on October 2, 2026, worth about $967,448. Officer Sean Maduck parted with 25,000 shares on October 2, 2026, totaling $2,906,601. Director James N Wilson sold 10,000 shares at an average price of $114.81 on October 15, 2026, in a transaction worth $1,148,083 carried out under a planned trading arrangement.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. On July 29, 2026, Canaccord Genuity maintained its buy rating and raised its target from $135.00 to $150.00. Piper Sandler reiterated an overweight rating on July 30, 2026, lifting its target from $88.00 to $165.00. Canaccord Genuity reiterated its buy stance on July 30, 2026, pushing its target higher from $150.00 to $161.00. HC Wainwright & Co. maintained a buy rating on July 30, 2026, while boosting its target from $95.00 to $165.00, and followed up by reiterating that buy rating on September 18, 2026. Overall, the stock carries a consensus buy recommendation from five analysts with a mean price target of $141.00.

About Corcept Therapeutics

Corcept Therapeutics Incorporated discovers and develops treatments for severe metabolic, oncologic, endocrinologic, and neurologic conditions. Headquartered in Redwood City, California, the biotechnology firm advances clinical programs focused on cortisol modulation as the company advances its clinical pipeline.

Bottom Line

Institutional filings continue to provide visibility into how large money managers position themselves in the healthcare sector. Investors will look toward the upcoming earnings release on November 4, 2026, for further updates on financial performance.